trending Market Intelligence /marketintelligence/en/news-insights/trending/7fvkblfcjxzyjagueigt5g2 content esgSubNav
In This List

BioSig Technologies seeks US FDA approval for cardiac recording system

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


BioSig Technologies seeks US FDA approval for cardiac recording system

BioSig Technologies Inc. filed a 510(k) application with the U.S. Food and Drug Administration for its PURE EP System.

The Los Angeles-based medical device company is seeking approval for the surface electrocardiogram and intracardiac multichannel recording system, which aims to produce high-fidelity heart recordings during electrophysiology studies and catheter ablation procedures.

Catheter ablation is a procedure to treat atrial fibrillation, the most common form of quivering or irregular heartbeat known as arrhythmia. Atrial fibrillation affects 6.1 million people in the U.S., increasing their risk of stroke by 4 to 5 times.

BioSig Technologies said it has conducted 11 pre-clinical studies and one clinical trial between 2015 and 2018.